Journal: Frontiers in Physiology
Article Title: Piezo1-pannexin-1-P2X 3 axis in odontoblasts and neurons mediates sensory transduction in dentinal sensitivity
doi: 10.3389/fphys.2022.891759
Figure Lengend Snippet: Time-dependence of pharmacological effects of P2X 3 receptor (A-317491) and PANX (mefloquine and 10 PANX) antagonist on dentinal sensitivity (A–C) Time-dependent effects of A-317491 (A; n = 6, 0.3 nmol/g (weight) i.v.), mefloquine (B; n = 7, 0.03 mg/g (weight) p.o.), and 10 PANX (C; n = 8, 2.58 nmol/g (weight) i.v.) (upper white boxes) on nociceptive scores following cold water stimulation. Prior to the systemic administration of A-317491, mefloquine, or 10 PANX to the dentin-exposed rats, nociceptive scores were determined as the control values (white circles). Several minutes after these measurements, A-317491 (A) , mefloquine (B) , or 10 PANX (C) was administered to the rats. The cold water stimuli-induced nociceptive scores were measured repeatedly at 10, 60, 120, 180, 240, 300, and 360 min later each (black circles in A to C; see also Materials and Methods). Each point denotes the mean ± SE of the number of experiments. Significant differences in the scores compared to control values are denoted by asterisks: * p < 0.05. (D) Summary bar graphs showing the mean nociceptive scores in the dentin-exposed group of rats without any treatment (control; withe columns) and their minimum values (during the entire period of administration) in dentin-exposed rats treated with A-317491 ( n = 6), mefloquine ( n = 7) and 10 PANX ( n = 8) (black columns). Each bar represents mean ± SE of the number of experiments. Significant differences between columns (shown by solid lines) are denoted by asterisks: * p < 0.05.
Article Snippet: The stock solutions of the reagents used included A-317491, a P2X 3 receptor antagonist (Sigma-Aldrich); 10 PANX, a selective PANX-1 blocker; and GsMTx-4, a selective Piezo1 channel blocker (R&D Systems, Inc, Minneapolis, United States) were prepared in sterilized PBS (Life Technologies, Ltd, Paisley, United Kingdom) and diluted with physiological saline (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) to the appropriate concentration for administration.
Techniques: